HER2 Inhibition in Gastric Cancer-Novel Therapeutic Approaches for an Established Target

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Aug 12

PMID 35954487

Authors

Caroline Fong

Ian Chau

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is a leading cause of cancer-related deaths globally. Human epidermal growth receptor 2 (HER2) overexpression of gene amplification is present in 20% of gastric cancers and defines a subset amenable to HER2-directed therapeutics. The seminal ToGA study led to routine use of the monoclonal antibody trastuzumab in conjunction to platinum-fluoropyridimine first-line chemotherapy for HER2-positive gastric cancers as standard-of-care. Although limited progress was made in the decade following ToGA, there is now an abundance of novel therapeutic approaches undergoing investigation in parallel. Additionally, new data from randomised trials have indicated efficacy of the antibody-drug conjugate trastuzumab deruxtecan in chemorefractory patients and increased responses with the addition of first-line immune checkpoint blockade to trastuzumab and chemotherapy. This review will outline the data supporting HER2 targeting in gastric cancers, discuss mechanisms of response and resistance to HER2-directed therapies and summarise the emerging therapies under clinical evaluation that may evolve the way we manage this subset of gastric cancers in the future.

Citing Articles

EGFR-directed antibodies promote HER2 ADC internalization and efficacy.

Gupta A, Michelini F, Shao H, Yeh C, Drago J, Liu D Cell Rep Med. 2024; 5(11):101792.

PMID: 39437778 PMC: 11604483. DOI: 10.1016/j.xcrm.2024.101792.

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON).

Tobias J, Maglakelidze M, Andric Z, Ryspayeva D, Bulat I, Nikolic I Clin Cancer Res. 2024; 30(18):4044-4054.

PMID: 39028916 PMC: 11393538. DOI: 10.1158/1078-0432.CCR-24-0742.

Clinical Pathological and Immunohistochemical Correlations in Gastric Cancer.

Andronic M, Scripcariu D, Palaghia M, Trofin A, Bejan V, Scripcariu V Diagnostics (Basel). 2024; 14(13).

PMID: 39001256 PMC: 11241519. DOI: 10.3390/diagnostics14131367.

Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma.

Kuwata T Pathol Int. 2024; 74(6):301-316.

PMID: 38651937 PMC: 11551831. DOI: 10.1111/pin.13427.

Pyrazole-based and N,N-diethylcarbamate functionalized some novel aurone analogs: Design, synthesis, cytotoxic evaluation, docking and SAR studies, against AGS cancer cell line.

Lathwal E, Kumar S, Sahoo P, Ghosh S, Mahata S, Nasare V Heliyon. 2024; 10(5):e26843.

PMID: 38463825 PMC: 10920165. DOI: 10.1016/j.heliyon.2024.e26843.

References

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K . Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017; 18(11):1512-1522. DOI: 10.1016/S1470-2045(17)30604-6. View

Shitara K, Bang Y, Iwasa S, Sugimoto N, Ryu M, Sakai D . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020; 382(25):2419-2430. DOI: 10.1056/NEJMoa2004413. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. DOI: 10.1111/j.1365-2559.2008.03028.x. View

Thuss-Patience P, Shah M, Ohtsu A, Van Cutsem E, Ajani J, Castro H . Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017; 18(5):640-653. DOI: 10.1016/S1470-2045(17)30111-0. View

Fong C, Chau I . Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. Pharmacogenomics. 2021; 22(11):703-726. PMC: 8265282. DOI: 10.2217/pgs-2020-0090. View

Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes S, Simnica D . Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial. JAMA Oncol. 2022; 8(8):1150-1158. PMC: 9227706. DOI: 10.1001/jamaoncol.2022.2228. View

Iwata T, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T . A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Mol Cancer Ther. 2018; 17(7):1494-1503. DOI: 10.1158/1535-7163.MCT-17-0749. View

10.

Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X . Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021; 24(4):913-925. PMC: 8205919. DOI: 10.1007/s10120-021-01168-7. View

11.

Triulzi T, Regondi V, De Cecco L, Cappelletti M, Di Modica M, Paolini B . Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. Br J Cancer. 2018; 119(12):1487-1494. PMC: 6288086. DOI: 10.1038/s41416-018-0318-0. View

12.

Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M . Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2018; 22(3):518-525. PMC: 6476840. DOI: 10.1007/s10120-018-0887-x. View

13.

Koganemaru S, Shitara K . Antibody-drug conjugates to treat gastric cancer. Expert Opin Biol Ther. 2020; 21(7):923-930. DOI: 10.1080/14712598.2020.1802423. View

14.

Maron S, Chase L, Lomnicki S, Kochanny S, Moore K, Joshi S . Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clin Cancer Res. 2019; 25(23):7098-7112. PMC: 6891164. DOI: 10.1158/1078-0432.CCR-19-1704. View

15.

van der Lee M, Groothuis P, Ubink R, van der Vleuten M, van Achterberg T, Loosveld E . The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers. Mol Cancer Ther. 2015; 14(3):692-703. DOI: 10.1158/1535-7163.MCT-14-0881-T. View

16.

Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak D, Taub R . Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007; 13(17):5133-43. DOI: 10.1158/1078-0432.CCR-07-0507. View

17.

Bartley A, Washington M, Ventura C, Ismaila N, Colasacco C, Benson 3rd A . HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016; 140(12):1345-1363. DOI: 10.5858/arpa.2016-0331-CP. View

18.

Leal A, van Grieken N, Palsgrove D, Phallen J, Medina J, Hruban C . White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020; 11(1):525. PMC: 6985115. DOI: 10.1038/s41467-020-14310-3. View

19.

Janjigian Y, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O . The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021; 600(7890):727-730. PMC: 8959470. DOI: 10.1038/s41586-021-04161-3. View

20.

Shah M, Xu R, Bang Y, Hoff P, Liu T, Herraez-Baranda L . HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric.... J Clin Oncol. 2017; 35(22):2558-2567. DOI: 10.1200/JCO.2016.71.6852. View